Gyre Therapeutics, Inc.
GYRE
$7.01
-$0.64-8.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,640.40% | 221.17% | -87.47% | -64.18% | 99.90% |
| Total Depreciation and Amortization | 39.00% | 45.84% | 181.14% | 28.92% | 62.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 682.32% | 53.56% | 41.18% | 14.23% | -99.30% |
| Change in Net Operating Assets | -155.02% | -43.19% | 95.38% | 20.14% | -135.56% |
| Cash from Operations | -103.95% | 170.92% | 138.01% | -104.47% | -182.08% |
| Capital Expenditure | -321.54% | 3.61% | 82.42% | 47.19% | 102.80% |
| Sale of Property, Plant, and Equipment | -92.03% | 100.00% | -91.74% | -98.00% | -17.37% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 189.76% | 65.72% | 60.14% | 129.66% | -57.53% |
| Cash from Investing | 192.22% | 47.76% | 63.23% | 127.24% | -249.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -76.11% | -86.63% | 8,638.91% | 122.64% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 730.00% | -1,312.61% | -- | -- |
| Cash from Financing | -67.01% | 12.65% | 14,227.56% | 104.26% | -61.44% |
| Foreign Exchange rate Adjustments | 149.80% | 10.38% | 162.82% | 208.70% | -210.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.79% | 1,793.07% | 256.68% | 186.79% | -154.55% |